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Summary
Background. Post chemotherapy Granulocyte colony stimulating factor (G-CSF) reduces leucopenia, while G-CSF
priming shortly before chemotherapy increases myelotoxicity. We performed a trial with a two-schedule crossover
design to determine the optimal G-CSF schedule for densiﬁed 2-weekly chemotherapy.
Methods. During 2-weekly chemotherapy days 1 and 2, G-CSF was given on days 3–10, with a G-CSF-free
interval before the next chemotherapy cycle of 5 days, or on days 3–13, with a G-CSF-free interval of 2 days. In
schedule A, cycle II was preceded by a 5 days, cycle III and IV by a 2 days and cycle V by a 5 days G-CSF free
interval. In schedule B, this was 2, 5, 5, and 2 days, respectively.
Results. Intra-patient comparison for cycles II versus III and cycles IV versus V showed that platelet (PLT) nadir
count was signiﬁcantly lower for cycles preceded by a 2-days compared to a 5-days G-CSF free interval: mean
diﬀerence 45.7 · 109/l (95% CI 33.2–58.2, p = 0.0001). Neutrophil count did not diﬀer signiﬁcantly (p = 0.85).
Conclusion. Timely withdrawal of G-CSF in dose-dense chemotherapy reduces chemotherapy-related throm-
bocytopenia. Leucopenia was not aggravated, reﬂecting a protective eﬀect of post-chemotherapy G-CSF.
Background
Granulocyte colony stimulating factor (G-CSF) and
granulocyte macrophage colony stimulating factor
(GM-CSF) have shown to be eﬀective in reducing both
the severity and duration of chemotherapy-induced
neutropenia [1]. The availability of these growth factors
has facilitated the study on dose-escalation and dose-
densiﬁcation of chemotherapy [2, 3]. In general, it is
advised to give G(M)-CSF for an average of 10 days,
starting 24 h after the end of chemotherapy [4].
Upfront administration of hematopoietic growth
factors has also been studied. This is based on the idea
of expanding the bone marrow progenitor pool before
the administration of cytotoxic medication [5]. How-
ever, GM-CSF and G-CSF have diﬀerent ‘priming’-ef-
fects. While both growth factors result in an increase in
numbers of bone marrow progenitor cells, there is an
abrupt decline in number of progenitor cells in S-phase
after discontinuing GM-CSF administration,
while the progenitor cells are still rapidly proliferating
for 2–4 days after cessation of G-CSF [6–8]. This ex-
plains the clinical observation, that upfront priming
with GM-CSF – before the administration of the ﬁrst
chemotherapy cycle – is myeloprotective [9, 10], while
upfront administration of G-CSF – till 48 h before the
delivery of chemotherapy – only aggravates the myelo-
suppression [5, 11, 12].
These observations have not fully been appreciated
in the design of dose-densiﬁcation studies or guidelines
on the use of hematopoietic growth factors. In the
reported 2-weekly chemotherapy regimens G-CSF was
continued until shortly before the next chemotherapy
cycle, since post chemotherapy G-CSF was administered
for the usual 10 days. And, in some of these studies
myelotoxicity was increased in these densiﬁed treatment
arms [13–16]. We hypothesized that the negative ‘prim-
ing’ eﬀect of post chemotherapy G-CSF in the prior
cycle may have caused the excess myelotoxicity on the
subsequent cycle. In case we would be able to proof
this hypothesis, the clinical beneﬁt of post chemotherapy
G-CSF can be enhanced by increasing the window
of time between interruption of the G-CSF and re-in-
itiation of the next chemotherapy cycle to 5 days, that is
beyond the aforementioned 2–4 days of G-CSF-induced
bone marrow proliferation. Therefore, the present
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study was undertaken to determine whether a shortened
regimen of daily G-CSF administration in relation to
2-weekly chemotherapy was beneﬁcial.
Patients and methods
Study design
The here reported study on the optimal G-CSF schedule
during 2-weekly chemotherapy was part of a larger
phase II study in which the eﬃcacy of a 2-weekly che-
motherapy regimen, delivered on days 1 and 2 of each
cycle, will be determined.
To evaluate the eﬀect of two diﬀerent G-CSF
schedules on hematological recovery, post chemother-
apy G-CSF was started at day 3 and administered for a
total of 8 days (days 3–10) or for a total of 11 days (days
3–13). Patients acted as their own control, and were
treated either according to schedule A or according to
schedule B (Figure 1). So, there were no comparisons
between diﬀerent patients. In schedule A, the duration
of G-CSF administration for cycle I through V was: 8,
11, 11, 8 and 8 days, respectively, with a G-CSF free
interval preceding cycle II through V of 5, 2, 2
and 5 days, respectively. In schedule B, the duration of
G-CSF administration for cycle I through V was: 11, 8,
8, 11 and 11 days, respectively, with a G-CSF free
interval preceding cycle II through V of 2, 5, 5 and
2 days, respectively. Intra-patient comparisons on
peripheral blood cell counts were done for cycle II ver-
sus cycle III and for cycle IV versus cycle V. Of note, for
these coupled cycles the duration of G-CSF treatment
was the same, while the G-CSF free interval before the
chemotherapy administration was the only diﬀerence: 5
versus 2 days or 2 versus 5 days.
Twenty-six patients were registered to participate in
the G-CSF-scheduling-part of the study. To be assess-
able, patients had to receive at least 3 chemotherapy
cycles with at least 2 comparator cycles (cycles II and III
and ideally also IV and V), provided that the time
frame was precisely followed (2-weekly chemotherapy
and G-CSF according schedule A or B) and provided
that the comparator cycles were delivered at the same
dosage. As a result, 11 patients were not assessable: 1
patient went oﬀ study after only 2 cycles, 1 patient died
after 1 cycle, 4 patients did not receive G-CSF according
to schedule (doctor’s mistake) and in the remaining 5
patients none of the cycles were comparable due to dose-
reduction and/or delay for several reasons.
Patient selection
Patients with locally advanced ormetastatic breast cancer
aged between 18 and 70 years with a life expectancy of
over 3 months and an ECOG performance status 0–2
were considered eligible. Prior hormonal treatment was
allowed as well as radiotherapy, if recovered from acute
toxicity and no more than 20% of the total bone marrow
compartment was involved. Prior adjuvant chemother-
apy was allowed (in case of adjuvant classical CMF at
least 6 months ago), but prior chemotherapy for ad-
vanced disease was not allowed. Inclusion required a
white blood cell (WBC) count ‡ 3.0 · 109/l, platelet
(PLT) count ‡ 100 · 109/l, creatinine-clearance (60 ml/
min (Cockroft), and bilirubin £ 25 micromol/l. During
the study no other anti-tumor treatment or concomitant
therapy with non-steroidal anti-inﬂammatory drugs, tet-
racyclines, phenytoin, sulphonamides or high dose vita-
min C were permitted. Written informed consent was
obtained from all patients. The hospital ethical review
board approved the protocol.
Treatment plan
Chemotherapy
Chemotherapy consisted of cyclophosphamide 700 mg/
m2, methotrexate 40 mg/m2 and 5-ﬂuorouracil 600 mg/
m2 on days 1 and 2 intravenously every two weeks.
Folinic acid started 24 h after the last administration of
methotrexate in a total dose of 120 mg (8 · 15 mg
orally every 6 h). A total of six cycles was planned for
each patient, unless serious complications or progressive
disease prohibited continuation of treatment.
G-CSF
To facilitate the delivery of 2-weekly CMF chemother-
apy, G-CSF (ﬁlgastrim, Amgen B.V. Breda, the
Figure 1. Schematic representation of G-CSF schedules.
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Netherlands) was administered subcutaneously once a
day, starting 24 h after each CMF cycle (on day 3)
in a dose of 300 lg (weight £ 75 kg) or 480 lg
(weight >75 kg), according to schedule A or B
(Figure 1).
Myelotoxicity
To evaluate bone marrow suppression, peripheral blood
cell counts and diﬀerentiation were measured on days 1,
8, 10, 12 and 15 of each 2-weekly cycle.
Also clinical events related to myelotoxicity as
infection with or without neutropenia, need of red blood
cell or PLT transfusion and haemorrhage were docu-
mented.
Dose-modiﬁcations
Chemotherapy was delayed for 1 week or longer as
necessary, if WBC counts were (3.0 · 109/l and/or PLT
counts (100 · 109/l. When the delay was more than
2 weeks, the patient went oﬀ study. Dose adjustments
were recommended in case of absolute neutrophil count
(ANC) < 0.5 · 109/l for more than 7 days, ANC
<0.5 · 109/l complicated by fever >38.5 C lasting
>2 days, sepsis or PLT count < 25 · 109/l. Dose
adjustments were also recommended in case of non-
haematological toxicity. Note that dose modiﬁcations
could lead to exclusion of the involved cycles or of the
patient from analysis of myelotoxicity.
Statistical analysis
The G-CSF part of the trial was designed as a four-
period, two-schedule crossover design (Figure 1). Pa-
tients acted as their own control. Due to the four-period
design the only variable was the G-CSF free interval in
the preceding cycle, since compared cycles were identical
in chemotherapy dose, interval between cycles and post
chemotherapy G-CSF duration. A cross-over design
was used to ensure that both a long followed by a short
G-CSF free interval (schedule A cycle II and III) op-
posed to a short followed by a long G-CSF free interval
(schedule B cycle II and III) could be assessed in order
to exclude a bias from a period eﬀect (cumulative che-
motherapy-dose). In case patients would only be treated
according to schedule A and myelotoxicity was shown
to be more severe in cycle III than in II, it is not possible
to determine whether this increased toxicity in cycle III
would be due to the preceding short G-CSF free interval
or to the higher cumulative total chemotherapy dose.
Using a crossover design, it is actually possible to cal-
culate both the size of the impact of G-CSF schedule
and the period eﬀect of two successive chemotherapy
cycles.
Based on the previous study, it was calculated that 44
cycles were needed to demonstrate a signiﬁcant diﬀer-
ence (power of 90%, one-sided signiﬁcance level of 5%)
at a G-CSF free-interval eﬀect on nadir ANC count of
the next cycle of 0.5 · 109/l assuming a residual stan-
dard deviation of 0.8 · 109/l. This last assumption was
based on within- patient estimates.
The nadir blood cell counts were analyzed using a
linear mixed model. In this model the within-patient
comparison was accomplished by assuming a subject-
speciﬁc random eﬀect. Furthermore, as independent
ﬁxed eﬀects, a period eﬀect and the eﬀect of G-CSF-free
interval (5 or 2 days) on nadir blood cell counts of the
next cycle were added to the model. 95% Conﬁdence
intervals (CI) were calculated for the eﬀect of G-CSF
free interval on nadir blood counts of the next cycle. All
analyses were done within the framework of linear
mixed models for repeated measurements using proce-
dure Mixed of the SAS package.
Results
Patient characteristics
In total, 40 chemotherapy cycles were evaluated
(Figure 2). Five patients received 4 comparator cycles and
ten patients 2 comparator cycles. Eight patients were
treated according to schedule A and 7 according to
schedule B.
The patient characteristics are summarized in
Table 1. Ten patients had metastatic disease of which
5 received prior adjuvant chemotherapy (CMF or FEC
Figure 2. Patient inclusion and assessed cycles.
Table 1. Patient characteristics at baseline of all 15 assessable patients
Median Age (range, years) 48 (37–67)
ECOG Performance status (N)
0 5
1 10
Locally advanced (N) 5
Metastatic (N) 10
Prior adjuvant chemotherapya (N) 5
Median WBC (range, · 109/l) 6.8 (4–11.4)
Median PLT count (range, · 109/l) 318 (178–504)
Median Hb count (range, mmol/l) 7.9 (6.4–9.1)
Median creatinine clearance (range, ml/min) 86 (59–143)
aInterval at least 6 months in all patients.
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(5-ﬂuorouracil, epirubicine and cyclophosphamide).
Interval to prior chemotherapy ranged from 6 months
to 15 years.
PLT nadir count
In schedule A, mean PLT nadir counts in cycles II and V
were higher than in their respective counterparts, cycles
III and IV, and the opposite occurred in schedule B.
Results are summarized in Table 2 and Figure 3. PLT
nadir count in cycles preceded by a 5-days G-CSF-free
interval was signiﬁcantly higher compared to cycles
preceded by a 2-days G-CSF-free interval (mean diﬀer-
ence of 45.7 · 109/l; 95% CI 33.2–58.2, Table 3)
(Table 4). A PLT nadir count less than 100 · 109/l was
seen in 20 cycles after a 2-days G-CSF – free interval
compared to only 11 cycles after a 5-days G-CSF – free
interval. A PLT nadir count less than 25 · 109/l was
observed in 4 cycles, all of them preceded by a 2-days
G-CSF-free interval. Median PLT nadir count occurred
on day 10 (range day 8–15) regardless of the preceding
G-CSF-free interval.
Over the entire treatment period the mean nadir
values of PLT count dropped. The mean PLT nadir was
33.8 · 109/l higher in cycle II compared to cycle V
(when schedule A and B are combined, p = 0.0003).
There was no signiﬁcant diﬀerence in mean PLT count
on day 15 of the next cycle (data not shown).
WBC and ANC nadir counts
WBC and ANC count were not signiﬁcantly diﬀerent
for cycles preceded by a 2-days versus a 5-days G-CSF-
free interval (1.3 versus 1.6 · 109/l, p = 0.24, and 0.81
versus 0.87 · 109/l, p = 0.85, respectively, see also
Table 3), nor was the moment on which the nadir count
occurred (median on day 10). Over the entire treatment
period, there was no signiﬁcant eﬀect seen on WBC and
ANC nadir values when respectively cycle II, III or IV
were compared to cycle V (p = 0.33).
Hemoglobin nadir counts
Hemoglobin (Hb) nadir counts (5.9 and 5.8 mmol/l
respectively, p = 0.12,see also Table 3) and moment of
nadir (median on day 10) were not signiﬁcantly diﬀerent
for cycles preceded by a 2-days versus a 5-days G-CSF-
free interval. Over the entire treatment period, the mean
nadir values of Hb level in cycle V signiﬁcantly dropped
respectively by 1.24 mmol/l compared to cycle II,
0.53 mmol/l compared to cycle III and 0.41 mmol/l
compared to cycle IV (p = 0.0001).
Clinical events
In none of the assessed cycles clinical overt hemorrhage
requiring transfusion or episodes of febrile neutropenia
were reported.
Figure 3. Mean PLT nadir count per cycle. For patients treated by
schedule A, cycle II was preceded by a 5-days G-CSF free interval, cycle
III and IV by a 2-daysG-CSF free interval, and cycle V again by a 5-days
G-CSF free interval. For patients treated by schedule B, cycle II was
preceded by a 2-days G-CSF free interval, cycle III and IV by a 5-days
G-CSF free interval, and cycle V again by a 2-days G-CSF free interval.
Comparison of blood cell counts for cycles II versus III and cycles IV
versus V shows that PLT nadir count is signiﬁcantly lower for cycles
preceded by a short 2-daysG-CSF free interval (for 95%CI see Table 2).
Table 2. Mean nadir PLT count · 109/l per cycle
Schedule Mean PLT nadir count · 109/l (95%CI)
Comparing cycles II versus III Comparing cycles IV versus V
G-CSF free
(days)
Cycle II G-CSF free
(days)
Cycle III G-CSF free
(days)
Cycle IV G-CSF free
(days)
Cycle V
Aa 5 133.0 (109–157) 2 38.6 (21–46) 2 63.2 (47–79) 5 96.4 (56–136)
Bb 2 68.7 (45–92) 5 81.0 ( 53–109) 5 91.3 (84–98) 2 54.7 (52–56)
aBased on respectively 6, 6, 5, 5 cycles for schedule A and b 6, 6, 3, 3 cycles for schedule B.
Table 3. Diﬀerences in mean nadir counts in cycles after 5 versus
2 days G-CSF-free interval
Diﬀerence 5 days
versus 2 days (95% CI)
p-value
PLT · 109/l 45.7 (33.2–58.2) 0.0001
WBC · 109/l 0.29 ()0.21–0.80) 0.24
ANC · 109/l 0.06 ()0.60–0.73) 0.85
Hb mmol/l 0.16 ()0.05–0.38) 0.12
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Dose reduction or delay in all 26 patients
Considering all 26 initially registered patients, 51 of 133
cycles were dose-reduced or delayed. In 30 cycles (59%)
this was PLT-related, that is in 5 cycles a PLT nadir
count of less than 25 · 109/l necessitated dose reduction
and in 25 cycles a PLT count of less than 100 · 109/l on
the planned day of start necessitated postponement of
the next chemotherapy cycle. In 63% of these 30 cycles
the preceding G-CSF-free interval was 2-days, and in
37% of cycles the G-CSF-free interval was 5 days.
Discussion
This is the ﬁrst study ever reported, in which the eﬀect of
two diﬀerent G-CSF schedules was evaluated in order to
determine a preferential G-CSF schedule during 2-
weekly chemotherapy. Based on prior reports, the
clinical beneﬁt of post chemotherapy G-CSF during
dose-densiﬁed chemotherapy may theoretically be
enhanced by increasing the time between interrup-
tion of G-CSF and re-initiation of chemotherapy
beyond 2–4 days. For this purpose, G-CSF was given
during 2-weekly chemotherapy either on days 3–10, with
a G-CSF-free interval before the next chemotherapy
cycle of 5 days, or on days 3–13 with a G-CSF-free
interval before the next chemotherapy cycle of 2 days.
The G-CSF schedule appeared to have a large impact on
the degree of thrombocytopenia of the next chemo-
therapy cycle. The mean PLT nadir count was 46 · 109/l
lower following a preceding ‘short’ 2-days G-CSF-free
interval compared to a ‘long’ 5-days G-CSF-free interval.
Previously, we reported on the results of a study in
twelve patients with relapsed small cell lung carcinoma.
[11] Patients were treated with two 4-weekly chemo-
therapy cycles and 6 days G-CSF priming was given till
48 h before the ﬁrst chemotherapy cycle only or till 48 h
before the second cycle only with patients acting as their
own control. G-CSF priming was shown to increase
both the chemotherapy-associated leucopenia and
thrombocytopenia. In that study no post-chemotherapy
G-CSF was given. The results of the current study
suggest that a possible negative eﬀect on WBC nadir
count of the short G-CSF free interval before the next
chemotherapy cycle can indeed be compensated for
by the use of post-chemotherapy G-CSF. But, post-
chemotherapy G-CSF during the next cycle cannot
protect against the negative priming eﬀect on PLT nadir
counts.
Thrombocytopenia is often reported as an important
side eﬀect of dose dense chemotherapy schedules and
hypothesized to be a consequence of cumulative che-
motherapy dose.[14, 13] Our results do conﬁrm a sig-
niﬁcant eﬀect of cumulative dose on Hb and PLT nadir
counts: the mean Hb nadir was 1.24 mmol/l higher in
cycle II versus cycle V (p = 0.0001) and the mean PLT
nadir count was 33.8 · 109/l higher in cycle II versus
cycle V (p = 0.0003). However, mean PLT nadir count
did not decline gradually during the course of treatment:
it was higher in cycle V than in cycle III and IV for
schedule A for example (Table 2). The double cross over
design permitted to demonstrate that the scheduling of
G-CSF aﬀects thrombocytopenia for an even larger
degree (diﬀerence in mean PLT nadir count 46 · 109/l,
95% CI 33.2–58.2, p = 0.0001). Although the number
of patients and cycles assessed in this study is only
modest, the 95% CI permits to conclude that the dura-
tion of G-CSF-free interval is of importance.
We observed that the majority of PLT-related dose
reductions or delays occurred in cycles following a short
G-CSF-free interval (19 out of 30 cycles), so one may
hypothesize that earlier discontinuation of G-CSF
before the (re-)start of chemotherapy can contribute to
maintain the delivery of planned chemotherapy dose
and dose-intensity. As mentioned before, in our study
dose and dose-intensity in the assessed cycles are by
deﬁnition the same. But, de Wit et al randomized 36
breast cancer patients both to receive pre- and
post chemotherapy G-CSF or only post chemotherapy
G-CSF [12]. They found that in patients receiving
G-CSF until 48 h before chemotherapy more frequent
dose reductions because of thrombocytopenia were
applied than in those patients who did not receive
pre-chemotherapy G-CSF. Also in children with
neuroblastoma treated with multiple cycles of strongly
myelosuppressive alkylator-based combination chemo-
therapy, prophylactic use of G-CSF hastened ANC
recovery but did not result in augmented dose intensity
and was associated with prolonged thrombocytopenia
(compared to a historical control group) [17].
The results reported here show, that there is an
impact of the duration of the G-CSF-free interval before
the next chemotherapy cycle on peripheral blood counts,
Table 4. Period eﬀect: impact of cumulative chemotherapy dose
Mean diﬀerence in nadir count compared to cycle V#
PLT · 109/l (SEM) WBC · 109/l (±SEM) ANC · 109/l (SEM) Hb mmol/l (SEM)
Cycle II versus V# 33.81 (±9.2) 0.28 (±0.39) 0.21 (±0.45) 1.24 (±0.16)
Cycle III versus V# )6.97 (±9.0) 0.62 (±0.38) 0.66 (±0.45) 0.53 (±0.15)
Cycle IV versus V# 4.07 (±9.2) )0.01 (±0.37) )0.24 (±0.46) 0.41 (±0.16)
p-value 0.0003 0.33 0.35 0.0001
Cycles of schedule A and B collectively. SEM = standard error of mean.
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but the underlying mechanism(s) for the eﬀect of G-CSF
schedule on PLT count is (are) not entirely clear. After 2–
4 days cessation of G-CSF treatment the bone marrow
progenitor cells are still rapidly proliferating with pro-
genitor cells in S-phase ranging from 38 ± 5
to 63 ± 8% compared with 26 ± 9 to 39 ± 8% before
G-CSF treatment [6, 7]. This means that after a 2 days
G-CSF-free interval compared to a 5 days interval more
progenitor cells are still proliferating and this might ex-
plain in part the observed impact of G-CSF schedule on
myelotoxicity. A functional G-CSF receptor on PLT’s
has been identiﬁed [18] and there is some in vivo evidence
that G-CSF has a suppressive eﬀect on the maturation of
mouse bone marrow megakaryocytes when monitored
by the DNA polyploidy [19]. When G-CSF is given to
healthy donors a drop in PLT count is seen by day 8 and
an even lower than pre-treatment PLT level by day 10
[20, 21]. Some authors hypothesize that splenic enlarge-
ment due to G-CSF induced extra-medullar hemato-
poiesis contributes to thrombocytopenia [21], but this is
contradicted by the observation in splenectomized mice
that circulating platelets decreased after 5FU-treatment
followed by G-CSF (whereas granulopoietic recovery
was accelerated and all stages of bone marrow megak-
aryocytopoiesis were decreased) [22]. Also redirection of
hematopoiesis towards neutrophil recovery and
subsequent suppression of other cell lines is often held
responsible. Again in splenectomized mice the delayed
start of G-CSF treatment for more than 5 days after
chemotherapy (5FU) showed no longer an impact on
granulopoiesis but PLT count was still signiﬁcantly re-
duced. This indicates that neither recruitment nor com-
petition between diﬀerent hematopoietic cell lines are
critical events in the cause of decreased PLT counts [22].
The importance of G-CSF schedule on myelotoxicity
might be of special concern since a long acting pegylated
G-CSF recently has been introduced. For patients a
major practical advantage of pegylated G-CSF is that
administration is needed only once a week. But the
variable and sometimes long half life indicates that the
eﬀect in an individual patient cannot be predicted and
may interfere with a safe interval to the next cycle,
especially during dose dense chemotherapy. Recently,
the results of a randomized phase III trial showed that a
single ﬁxed dose (6 mg) of pegylated G-CSF could be
administered eﬀectively and safely in a 3-weekly che-
motherapy schedule [23]. But, no published data are
available in dose dense chemotherapy yet. In another
trial with pegylated G-CSF, thrombocytopenia was
more frequent after chemotherapy in the highest dosage
group of 100 (g/kg compared to 20 and 60 (g/kg peg-
ﬁlgrastim or daily ﬁlgrastim [24]. These ﬁndings and our
results stress the importance of carefully determining the
optimal dose and timing of (peg)ﬁlgrastim in relation to
the planned chemotherapy regimen.
In conclusion, during 2-weekly densiﬁed chemother-
apy daily post chemotherapy G-CSF until 2 days before
the next cycle compared to post chemotherapy G-CSF
until 5 days before the next chemotherapy cycle signiﬁ-
cantly worsened the degree of thrombocytopenia. There
was no impact of G-SCF schedule on the degree of
leukopenia, reﬂecting a counterbalancing protective
eﬀect of post chemotherapy G-CSF in both the 8 day
and 10 day schedule. Timely withdrawal of G-CSF
during 2-weekly chemotherapy reduces chemotherapy-
related thrombocytopenia without jeopardizing ANC
recovery and therefore, may realize planned dose-
intensity increase.
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